Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.75) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.68) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Alnylam Pharmaceuticals Trading Down 1.6 %
Shares of ALNY stock opened at $143.80 on Thursday. Alnylam Pharmaceuticals has a twelve month low of $143.50 and a twelve month high of $218.88. The stock has a market cap of $18.11 billion, a P/E ratio of -40.39 and a beta of 0.39. The stock has a 50 day moving average of $150.77 and a 200 day moving average of $166.28.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on ALNY
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
Further Reading
- Five stocks we like better than Alnylam Pharmaceuticals
- Health Care Stocks Explained: Why You Might Want to Invest
- High-Yield Texas Instruments Could Hit New Highs Soon
- 3 REITs to Buy and Hold for the Long Term
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- Which Wall Street Analysts are the Most Accurate?
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.